- NSE
NGL Fine-Chem Limited
Healthcare NGLFINE
2164.20INR
360.70
(
20.00%)
Last update at
Day Range
52 Week Range
Fundamentals
- Previous Close 1803.50
- Market Cap 9198.47M
- Volume26,204
- P/E Ratio 43.71
- EBITDA 409.64M
- Revenue TTM 4084.63M
- Revenue Per Share TTM 659.18
- Gross Profit TTM 1964.81M
- Diluted EPS TTM 33.75
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Financials
Income Statement
Balance Sheet
Change in Cash
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Income before tax | 277.14M | 544.17M | 273.62M | 665.96M | 775.90M |
| Net income | 211.24M | 413.17M | 204.96M | 498.97M | 567.19M |
| Total Revenue | 3682.57M | 3386.88M | 2780.81M | 3128.27M | 2550.01M |
| Gross Profit | 1858.50M | 1696.07M | 1377.60M | 1658.36M | 1526.57M |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Total assets | 4333.91M | 3555.36M | 2870.79M | 2769.27M | 2077.66M |
| Intangible assets | 3.97M | 1.17M | 1.73M | 3.04M | 3.50M |
| Other current assets | 370.31M | 244.33M | 122.90M | 157.36M | 122.34M |
| Deferred long term liab | - | - | - | - | - |
| Non current assets other | - | - | - | - | - |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Change in Cash | 1.88M | -74.33M | 71.85M | -14.60M | 17.04M |
| Operating Cash | 358.22M | 204.65M | 352.86M | 138.25M | 273.54M |
| Free Cash Flow | -949.49M | -80.59M | 38.80M | -425.52M | 101.42M |
Peer Comparison
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change | Price | Market Cap (M) | P/E Ratio |
|---|---|---|---|---|
| NGLFINE NGL Fine-Chem Limited |
360.70 20.00% | 2164.20 | 9198.47 | 43.71 |
| GLAXO GlaxoSmithKline Pharmaceuticals Limited |
-22.40 -0.92% | 2412.90 | 406354.23 | 42.58 |
| PFIZER Pfizer Limited |
83.80 1.80% | 4751.40 | 222237.90 | 26.50 |
| SANOFICONR SANOFI CONS HEALTHC IND L |
-97.90 -2.23% | 4291.00 | 101612.67 | 46.61 |
| SANOFI Sanofi India Limited |
22.40 0.56% | 4037.60 | 95811.08 | 26.88 |
Profile
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, rafoxanide, diminazene aceturate, s-methoprene, carprofen, diminazene diaceturate, ractopamine HCI, toltrazuril, decoquinate, amitraz, marbofloxacin, flunixin meglumine, praziquantel, fenbendazole, and xylazine hydrochloride. It also provides human health pharmaceutical ingredients, including nitazoxanide and atovaquone; and intermediates and specialty chemicals comprising 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-ethyl glucamine. In addition, the company offers finished dosage forms, including diminazene aceturate granules and homidium chloride tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.
NGL Fine-Chem Limited
301, E Square, Mumbai, India, 400057
- 91 22 4084 2222
- https://www.nglfinechem.com
- Employees : 520
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Rahul Jayant Nachane | CEO, MD, Chief Ethics Counsellor & Exec. Director | 1964 |
| Mr. Rajesh Narayan Lawande | Whole Time Director & CFO | 1976 |
| Mr. Ahaan Nachane | VP | NA |
| Ms. Pallavi Pednekar | Company Sec. & Compliance Officer | NA |
| Mr. Arun G. Lawande | Consultant | NA |
| Mr. Rahul Jayant Nachane ACA, B. Com, DBF, MMS | CEO, MD, Chief Ethics Counsellor & Executive Director | 1964 |
| Ms. Pallavi Satish Pednekar | Company Secretary & Compliance Officer | NA |
| Mr. Ahaan Nachane | Vice President | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data ("EODHD") on an 'as is' basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.